Oculus Research — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$189,269	15
2024	Research	$2,975	1
2023	Research	$65,302	5
2022	Research	$22,423	2
2020	Research	$3,484	4

Breakdown

Who paid Research payments · program years 2020–2025

Oyster Point Pharma, Inc. $189,269 15 payments
Bausch & Lomb Americas Inc. $87,725 7 payments
Ocular Therapeutix, Inc. $3,484 4 payments
Alcon Research LLC $2,975 1 payment

Studies the money was for Research payments · program years 2020–2025

OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity (LYNX-3) $183,071 12 payments
A Multicenter, Double-Masked, Randomized, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of Atropine 0.1% and 0.01% Ophthalmic Solutions Administered With a Microdose Dispenser for the Reduction of Pediatric Myopia Progression $65,302 5 payments
A Multicenter, Double-Masked, Randomized, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of Atropine 0.1% and 0.01% Ophthalmic Solutions Administered With a Microdose Dispenser for the Reduction of Pediatric Myopia Progression $22,423 2 payments
Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (LYNX-2) $6,198 3 payments
A Prospective Multicenter Open Label Extension Study to Evaluate the Long Term Safety of OTX TP $3,484 4 payments
COMET-Ocular Surface Characteristics Study $2,975 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.